3rd Quarter - Report

ARENTFOX SCHIFF LLP for KEMPHARM, INC.

Firm
Client
Income
$30,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Prodrug therapies and improving abuse deterrence and consumer safety Anti-opioid abuse legislation

LobbyistCovered position, as disclosed
PHILIP ENGLISH —
NORMAN FREDERICK LENT —
SONJA NESBIT —

Contacted: Office of Natl Drug Control Policy (NDCP); HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS)

Pharmacy PHA

FDA regulation of opioid abuse deterrent formulations H.R. 2430 (FDA Reauthorization Act of 2017), provisions relating to drugs H.R. 2025 (Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017), all provisions

LobbyistCovered position, as disclosed
PHILIP ENGLISH —
NORMAN FREDERICK LENT —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Office of Natl Drug Control Policy (NDCP)

Bills named: H.R. 2430 (115th), H.R. 2025 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.